# Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

> **NCT05899608** · PHASE3 · RECRUITING · sponsor: **Summit Therapeutics** · enrollment: 1600 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Ivonescimab Injection
- **BIOLOGICAL:** Pembrolizumab Injection

## Key facts

- **NCT ID:** NCT05899608
- **Lead sponsor:** Summit Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-26
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 1600 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05899608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05899608, "Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05899608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*